title: Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients.
abstract: The purpose of this study was to investigate the prognostic value of the expression of intercellular adhesion molecule 1 (ICAM-1), leukocyte function antigen 3 (LFA-3), human leukocyte differentiation antigen (HLA)-ABC, HLA-DR, and 5T4 with regard to disease-free survival in Dukes' B and C colorectal carcinoma patients. Forty-one patients (28 Dukes' B and 13 Dukes' C) were entered into this study. Immunocytochemistry was performed on cytospin preparations of enzymatically digested colorectal carcinoma cell suspensions. The frequency of metastases and the duration of disease-free survival were compared between the 25% lowest expressers and the 75% remaining patients for ICAM-1, LFA-3, HLA-ABC, and HLA-DR, and between the 25% highest expressers and the 75% remaining patients for 5T4. Low numbers of ICAM-1-expressing tumor cells were associated with a shorter disease-free survival (P < 0. 001), independent of Dukes' stage. High numbers of 5T4-expressing tumor cells were associated with shorter disease-free survival in Dukes' B patients (P = 0.04). Cox proportional hazard analysis indicated that low numbers of ICAM-1(+) and high numbers of 5T4(+) cells were independent prognostic factors with relative risks of 13. 0 (P = 0.0002) and 4.7 (P = 0.02), respectively. The combination of 5T4 and ICAM-1 marker information identified subgroups of patients with a good (high ICAM-1) or poor (low ICAM-1/high 5T4) prognosis. Neither a lack of HLA-ABC and LFA-3 expression nor the presence of HLA-DR on the tumor cells gave additional prognostic information. These findings demonstrate that low ICAM-1 and high 5T4 expression on tumor cells are prognostic markers, additional to Dukes' stage, for reduced disease-free survival in Dukes' B and C colorectal carcinoma patients.
authors.affiliation: Departments of Pathology, Surgery, and Oncology, Free University Hospital, 1081 HV Amsterdam, The Netherlands.
authors.forename: W M
authors.initials: WM
authors.lastname: Mulder
authors.forename: P L
authors.initials: PL
authors.lastname: Stern
authors.forename: M J
authors.initials: MJ
authors.lastname: Stukart
authors.forename: E
authors.initials: E
authors.lastname: de Windt
authors.forename: R M
authors.initials: RM
authors.lastname: Butzelaar
authors.forename: S
authors.initials: S
authors.lastname: Meijer
authors.forename: H J
authors.initials: HJ
authors.lastname: Adér
authors.forename: A M
authors.initials: AM
authors.lastname: Claessen
authors.forename: J B
authors.initials: JB
authors.lastname: Vermorken
authors.forename: C J
authors.initials: CJ
authors.lastname: Meijer
authors.forename: J
authors.initials: J
authors.lastname: Wagstaff
authors.forename: R J
authors.initials: RJ
authors.lastname: Scheper
authors.forename: E
authors.initials: E
authors.lastname: Bloemena
mesh_terms: D000368:Aged; D000951:Antigens, Neoplasm / Q000032:analysis; D001803:Blood Transfusion; D018968:CD58 Antigens / Q000032:analysis; D015179:Colorectal Neoplasms / Q000276:immunology / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006684:HLA-DR Antigens / Q000032:analysis; D015395:Histocompatibility Antigens Class I / Q000032:analysis; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000032:analysis*; D008297:Male; D008562:Membrane Glycoproteins / Q000032:analysis*; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D015996:Survival Rate; D013997:Time Factors
chemical_list: D000951:Antigens, Neoplasm; D018968:CD58 Antigens; D006684:HLA-DR Antigens; D015395:Histocompatibility Antigens Class I; D008562:Membrane Glycoproteins; C063709:trophoblastic glycoprotein 5T4, human; D018799:Intercellular Adhesion Molecule-1